Clear Cell Adenocarcinoma of the Kidney

Other names
Types
Causes (risk factors)
Symptoms
Diagnostic tests
Non-pharmacological treatments (therapies and other measures )
Drug treatments
Dietary molecular supplements
Immune-boosting and regenerative approaches
Surgeries (key procedures)
Prevention strategies
When to see doctors
What to eat and what to avoid
Frequently asked questions (FAQs)

Clear cell adenocarcinoma of the kidney is the same disease that doctors usually call clear cell renal cell carcinoma (clear cell RCC). It is a type of kidney cancer that starts from the tiny tubules in the kidney that filter blood. In this cancer, the tumor cells look pale or “clear” under the microscope because they are full of fat and sugar that are washed out during the lab process. Clear cell RCC is the most common kidney cancer in adults and makes up about 75–80% of all renal cell carcinomas.

Clear cell adenocarcinoma of the kidney, also called clear cell renal cell carcinoma (ccRCC), is the most common type of kidney cancer in adults. It starts in the tiny tubes (tubules) that filter waste from your blood. Under the microscope, the cancer cells look “clear,” like bubbles, because they are full of fat and sugar. This cancer often grows slowly at first, but it can spread to other parts of the body (metastasis) if not treated. Treatment usually includes surgery, medicines that target cancer blood supply, and immunotherapy drugs that help your immune system attack the cancer.

This tumor is malignant. That means it can grow into nearby kidney tissue, blood vessels, and nearby organs, and it can also spread (metastasize) to distant parts of the body such as the lungs, bones, liver, or brain. Clear cell RCC is often found by chance during an ultrasound or CT scan done for another reason, because many people do not have clear symptoms in the early stage.

Other names

Doctors and books may use several different names for this same disease. All of the names below refer to essentially the same tumor:

Clear cell renal cell carcinoma (ccRCC)
Clear cell carcinoma of the kidney
Clear cell adenocarcinoma of the kidney
Conventional renal cell carcinoma (older term that usually means clear cell type)
Hypernephroma (very old name, now mostly historical)

These names can be confusing, but they all describe a kidney cancer made of “clear” cells that arises in the filtering part of the kidney.

Types

Even though all of these tumors are “clear cell,” doctors still divide them into types or groups to help plan treatment and talk about prognosis. These “types” are really ways of classifying the same disease:

Localized clear cell RCC – The tumor is only inside the kidney and has not grown into major veins or spread to lymph nodes or distant organs. This is usually early stage (for example, stage I or II).
Locally advanced clear cell RCC – The cancer has grown outside the kidney into nearby fat, the adrenal gland, or major veins (such as the renal vein or inferior vena cava), or nearby lymph nodes, but there is no spread to distant organs yet.
Metastatic clear cell RCC – The cancer has spread to distant organs, most often the lungs, bones, liver, or brain. This stage needs systemic therapy such as targeted drugs or immunotherapy.
Hereditary clear cell RCC – The tumor happens as part of a genetic syndrome, most commonly von Hippel–Lindau (VHL) disease, where an inherited change in the VHL gene makes clear cell tumors more likely to form in both kidneys and in other organs.
Sporadic clear cell RCC – The tumor appears “out of the blue” in someone without a known inherited cancer syndrome; this is the most common situation.
Low-grade vs high-grade clear cell RCC – Under the microscope, some tumors have cells that look more calm and organized (low grade), while others look very abnormal and aggressive (high grade). High-grade tumors usually grow and spread faster.
Clear cell RCC with sarcomatoid or rhabdoid change – In some tumors, part of the cancer changes into very aggressive “sarcoma-like” cells. These mixed tumors behave more aggressively and often have a worse outlook.

Causes (risk factors)

For clear cell adenocarcinoma of the kidney, we do not usually talk about one single “cause.” Instead, doctors talk about risk factors that make this cancer more likely. Having one or more risk factors does not mean a person will definitely get cancer, and some people with no known risk factors still develop the disease.

Older age – Most people with clear cell RCC are older adults, often over 60 years of age. Cancer risk rises slowly as cells collect more genetic changes over time.
Male sex – Kidney cancer, including clear cell RCC, is about twice as common in men as in women. Lifestyle factors like smoking and some occupational exposures may partly explain this difference.
Cigarette smoking – Smoking is one of the strongest known risk factors. Harmful chemicals in tobacco smoke are filtered by the kidneys, damage kidney cells, and can lead to cancer-causing DNA changes.
Obesity (high body weight) – Extra body fat changes hormone levels, insulin, and inflammation in the body. These changes are linked to a higher risk of renal cell carcinoma, including clear cell type.
High blood pressure (hypertension) – Long-term high blood pressure can damage small blood vessels and kidney tissue and is a well-established risk factor for kidney cancer. Some blood pressure medicines may also play a role, but the main risk is from the high pressure itself.
Chronic kidney disease (CKD) – People with long-standing kidney damage or reduced kidney function have a higher chance of developing RCC, especially when the kidneys become small and scarred.
Long-term dialysis – Patients on dialysis for many years can develop acquired cystic kidney disease, and those cysts sometimes turn into clear cell RCC.
Acquired cystic kidney disease – In people with damaged kidneys, many cysts can form. Over time, cells in these cysts can become abnormal and may turn into clear cell cancer.
Family history of kidney cancer – Having a close relative (parent, brother, sister) with RCC slightly increases risk, suggesting that shared genes or shared environmental exposures are important.
Von Hippel–Lindau (VHL) syndrome – This inherited condition causes a defect in the VHL gene, which normally helps control cell growth and blood vessel formation. People with VHL have a high lifetime risk for multiple clear cell RCCs.
Other hereditary kidney cancer syndromes – Syndromes such as Birt–Hogg–Dubé or hereditary leiomyomatosis and RCC can also increase risk of clear cell or other RCC types, even though each one is rare.
Diabetes and metabolic syndrome – High blood sugar, abnormal cholesterol, and central obesity together (metabolic syndrome) are associated with a higher risk of RCC in many studies, possibly through chronic inflammation and hormonal changes.
Unhealthy diet – Diets rich in processed meats, red meat, and refined carbohydrates and low in fruits and vegetables may raise kidney cancer risk, while a diet high in plant foods appears protective.
Occupational exposure to trichloroethylene – Some workers exposed to this industrial solvent (used in metal degreasing and some cleaning processes) have a higher rate of RCC.
Occupational exposure to cadmium and other heavy metals – Cadmium and certain industrial chemicals may damage kidney cells and have been linked to an increased RCC risk in some studies.
Long-term use of certain painkillers – Older pain medicines (such as phenacetin, now banned in many countries) and heavy long-term use of some NSAIDs have been associated with kidney damage and possibly RCC in some reports, though evidence is weaker than for smoking or obesity.
Previous kidney radiation – Radiation therapy to the kidney area for another cancer can slightly increase the chance of kidney tumors many years later, though this is uncommon.
Living in regions with high kidney cancer incidence – Kidney cancer rates are higher in some high-income countries, probably because of combined effects of smoking, obesity, hypertension, and other lifestyle factors common in those populations.
Hormonal and growth factor changes – Obesity and metabolic problems raise levels of insulin and insulin-like growth factors, which can encourage abnormal cell growth in the kidney and contribute to cancer development.
Unknown or unexplained factors – In many patients, no clear risk factor is found. This reminds us that kidney cancer is complex and that random genetic changes inside kidney cells also play a role.

Symptoms

Many people with clear cell RCC have no symptoms at first, and the tumor is found on a scan done for another reason. When symptoms do occur, they may be due to growth of the tumor in the kidney, spread to other organs, or hormone-like substances made by the tumor (paraneoplastic syndromes).

Blood in the urine (hematuria) – The urine may look pink, red, or cola-colored, or blood may only be seen under the microscope. Blood appears when the tumor breaks small blood vessels inside the kidney.
Flank or side pain – Dull, aching pain on one side of the back or abdomen can occur when the tumor stretches the kidney capsule or presses on nearby tissues and nerves.
Lump or fullness in the abdomen – Sometimes a doctor or the patient can feel a mass or swelling in the side or belly if the tumor grows large. This is part of the “classic triad” but is now less common because tumors are found earlier.
Unexplained weight loss – Many patients lose weight without trying. This can be due to loss of appetite, changed metabolism, or inflammatory substances released by the tumor.
Fever not due to infection – Some people have repeated or long-lasting fevers, night sweats, or feeling hot and cold without any clear infection. These are paraneoplastic symptoms.
Tiredness and weakness (fatigue) – Cancer can cause low energy due to inflammation, poor sleep, loss of appetite, and anemia, so patients often feel very tired.
Anemia (low red blood cells) – Tumor-related inflammation or reduced production of erythropoietin by damaged kidneys can cause anemia, leading to paleness, shortness of breath on exertion, and dizziness.
High red blood cell count (erythrocytosis) – In some cases, the tumor makes too much erythropoietin, leading to extra red blood cells, headache, flushing, and a ruddy complexion.
High blood pressure – The tumor can produce renin or press on kidney vessels, which can cause or worsen hypertension, sometimes suddenly or severely.
Swelling of legs or ankles – Kidney cancer can raise pressure in veins or cause kidney failure, leading to fluid buildup and swelling, especially in the lower limbs.
Varicocele in men (especially on the left side) – A large left-sided varicocele can appear or worsen if the tumor blocks the testicular vein draining into the left renal vein.
Bone pain or fractures – If the cancer spreads to bones, patients may have persistent bone pain, tenderness, or broken bones after minimal injury.
Cough or shortness of breath – Spread to the lungs can cause chronic cough, chest pain, or breathlessness, sometimes with coughing up blood.
Liver-related symptoms – Rarely, patients develop liver test changes and symptoms of a liver problem even without liver metastasis (Stauffer syndrome). This is due to substances released by the tumor.
General feeling of being unwell (malaise) – Many people simply feel “not right,” with low energy, poor appetite, and vague discomfort, long before a definite diagnosis is made.

Diagnostic tests

Doctors use several kinds of tests to diagnose clear cell adenocarcinoma of the kidney, to see how far it has spread, and to check overall health before treatment. These tests include physical exam, manual bedside tests, lab and pathological tests, electrodiagnostic tests, and imaging tests.

Physical exam tests

Full physical examination – The doctor looks at the patient’s general condition, body weight, skin color, breathing, and level of comfort. They check for signs like weight loss, fever, anemia (pale skin), and swelling, which can suggest a chronic disease such as kidney cancer.
Blood pressure measurement – The doctor checks blood pressure with a cuff on the arm. Very high or difficult-to-control blood pressure can be a sign that the kidney tumor is making hormones like renin or is affecting kidney function.
Abdominal and flank inspection – The doctor carefully looks at the abdomen and sides for visible swelling, bulging, or asymmetry. A large kidney tumor can sometimes change the shape of the flank or make one side look fuller.
Checking for leg and ankle swelling – By looking at and pressing on the legs and ankles, the doctor can detect pitting edema. This swelling may come from kidney failure, low protein levels, or blockage of large veins by the tumor.

Manual tests (specific bedside maneuvers)

Abdominal palpation for a kidney mass – The doctor uses both hands to gently press into the abdomen and flanks to feel for a lump or enlarged kidney. In some patients, a firm, non-tender mass can be felt on one side, which raises suspicion for RCC.
Costovertebral angle (CVA) tenderness test – The doctor taps gently over the angle between the spine and the lower ribs on each side. Pain in this area can indicate kidney or ureter problems, including tumors, stones, or infection.
Manual lymph node examination – The doctor uses their fingers to feel lymph node areas in the neck, underarms, and groin. Enlarged, firm lymph nodes may mean that the cancer has spread through the lymphatic system.

Lab and pathological tests

Complete blood count (CBC) – This blood test measures red cells, white cells, and platelets. It can show anemia, high red cell counts, or abnormal platelets, which are common paraneoplastic findings in RCC.
Serum creatinine and estimated glomerular filtration rate (eGFR) – These blood tests tell how well the kidneys are working. They help doctors plan surgery and medicines and estimate how much healthy kidney function will be left after removing the tumor.
Liver function tests (LFTs) – Blood tests for liver enzymes and proteins can detect liver metastasis or paraneoplastic liver changes (like Stauffer syndrome), even when the liver itself is not invaded by tumor.
Serum calcium level – Clear cell RCC can cause high blood calcium (hypercalcemia) through bone metastasis or hormone-like substances. Measuring calcium helps detect this serious complication.
Urinalysis – A simple urine test looks for blood, protein, and other abnormalities. Even when urine looks normal, microscopic blood or protein can point to kidney disease or a tumor.
Urine cytology – In this test, urine is examined under a microscope to look for cancer cells that have shed from the urinary system. It is more useful for tumors of the renal pelvis and bladder but may be done as part of the evaluation.
Kidney tumor biopsy and histopathology – A radiologist may take a small sample of the kidney mass using a needle guided by ultrasound or CT. A pathologist studies the cells under the microscope and uses special stains to confirm clear cell type and grade.

Electrodiagnostic tests

Electrocardiogram (ECG) – This simple test records the heart’s electrical activity. It does not diagnose kidney cancer directly, but it is very important before surgery or systemic treatment to check for heart problems that might affect anesthesia or certain drugs.
Holter ECG or other heart rhythm monitoring – In some patients, especially older ones or those with symptoms, doctors may use longer-term ECG monitoring to detect hidden rhythm problems. Safe kidney cancer treatment often depends on knowing the heart is stable.

(Electrodiagnostic tests are mainly for overall fitness and treatment planning, not for detecting the kidney tumor itself.)

Imaging tests

Renal ultrasound – This test uses sound waves to create pictures of the kidneys. It is often the first imaging test when blood in the urine or kidney problems are suspected. It can show a solid mass, cyst, or obstruction.
Contrast-enhanced CT scan of abdomen and pelvis – CT is the main imaging test for RCC. Iodine contrast is injected into a vein, and detailed cross-section pictures show the size of the tumor, its blood supply, and spread to nearby structures or lymph nodes.
MRI of the abdomen – MRI uses a strong magnet and radio waves to create images without X-rays. It is especially useful if CT contrast is not safe (for example, in severe kidney failure) or to better see tumor invasion into big veins like the inferior vena cava.
Chest imaging (chest X-ray or CT chest) – Because clear cell RCC often spreads to the lungs, doctors routinely image the chest to look for small nodules or larger masses. This helps stage the cancer and choose the right treatment plan.

Non-pharmacological treatments (therapies and other measures )

Smoking cessation programs
Stopping smoking is one of the most powerful lifestyle treatments for clear cell kidney cancer. Counseling, nicotine replacement, or special stop-smoking clinics can help you quit and stay smoke-free. Quitting reduces the stress on your kidneys and may improve how you respond to cancer treatment. Studies show that people with kidney cancer who quit after diagnosis can live longer and have lower risk of cancer progression compared with those who keep smoking.
Healthy weight and nutrition counseling
Being overweight is a strong risk factor for kidney cancer and can also make treatment harder. A dietitian can help you plan meals with fruits, vegetables, whole grains, and lean protein so you can keep a healthy weight. This reduces inflammation and pressure on the kidneys. A healthy body weight also helps control blood pressure and blood sugar, which are linked to kidney cancer risk and outcomes.
Regular physical activity
Gentle, regular exercise such as walking, cycling, or light strength training can improve energy, mood, and sleep during and after treatment. Exercise may help control weight, lower blood pressure, and improve immune function. These changes can lower the chance of complications and may help you tolerate systemic drugs better. Your doctor or physiotherapist can design a safe program based on your stage and overall health.
Blood pressure control (non-drug strategies)
High blood pressure is both a risk factor and a common problem during treatment for clear cell kidney cancer. Non-drug steps include reducing salt in the diet, losing weight, exercising, and managing stress. These measures can reduce strain on blood vessels in the kidneys and may improve long-term kidney function, especially if you have only one kidney after surgery.
Diabetes and metabolic control education
High blood sugar and metabolic syndrome are linked to higher kidney cancer risk and worse outcomes. Lifestyle education about portion control, avoiding sugary drinks, and combining diet with activity can stabilize blood sugar. Better glucose control reduces inflammation and damage to kidney blood vessels, which supports overall health during cancer care.
Stress-reduction therapies (mindfulness, meditation, yoga)
Cancer causes heavy emotional stress, which can worsen pain, fatigue, and sleep problems. Mind-body therapies such as guided breathing, meditation, or gentle yoga calm the nervous system and lower stress hormones. This can improve quality of life, mood, and sometimes treatment adherence, because patients feel more able to handle appointments and side effects.
Psychological counseling and psycho-oncology
Talking with a psychologist or counselor trained in cancer care can help you cope with fear, sadness, and uncertainty. Therapy may use simple tools like problem-solving and cognitive behavioral methods to manage anxiety and depression. Better mental health supports better sleep, appetite, and energy, and can help you follow complex treatment plans for clear cell kidney cancer.
Support groups and patient education programs
Meeting other people with kidney cancer, either in person or online, can reduce feelings of isolation. Support groups share practical tips about managing side effects, diet, and work or family issues. Education sessions run by nurses or patient organizations teach you how clear cell kidney cancer behaves and what to expect from surgery and drugs. Informed patients often feel more in control and more engaged in decisions.
Pain management with physiotherapy and occupational therapy
Some patients have flank pain, bone pain from metastases, or muscle weakness from treatments. Physiotherapists can use stretching, gentle strengthening, and posture training to ease pain and improve movement. Occupational therapists can suggest tools and home changes to make bathing, dressing, and cooking easier. This non-drug pain care reduces the need for high doses of pain medicines.
Palliative care and symptom-control services
Palliative care is not only for the end of life. It focuses on relief of symptoms like pain, nausea, fatigue, or shortness of breath at any stage. A specialist team works with your oncologist to adjust lifestyle, schedule, and home support. Early palliative care has been shown in many cancers to improve quality of life and sometimes even survival, by keeping you strong enough to continue useful treatments.
Sleep hygiene and fatigue management
Clear cell kidney cancer and its treatments can cause severe tiredness. Simple steps such as a regular sleep schedule, a dark quiet bedroom, and limiting screens before bed can improve rest. Short daytime naps, light exercise, and pacing of daily tasks help manage fatigue. Better sleep supports immune function and mood, which may help you tolerate treatment better.
Renal-protective lifestyle (hydration and avoiding kidney toxins)
When one kidney is removed or damaged, protecting the remaining kidney is critical. Drinking enough water, avoiding unnecessary non-steroidal painkillers, and limiting contrast scans when possible help reduce extra kidney injury. This can prevent or slow chronic kidney disease and keep more treatment options open in the future.
Occupational and environmental exposure reduction
Some jobs and environments expose people to solvents, heavy metals, or other chemicals that can harm kidneys. Counseling about workplace safety, use of protective equipment, and sometimes job modification can reduce further damage. Lower exposure may not change the existing cancer, but it can protect the remaining kidney and overall health.
Nutritional support for treatment-related side effects
Systemic drugs can cause loss of appetite, taste changes, diarrhea, or mouth sores. A dietitian can suggest bland, soft, or high-calorie foods and simple eating schedules to keep energy intake adequate. This reduces weight loss and muscle wasting, helping you stay strong enough to receive life-saving cancer therapies.
Fall-prevention and bone-health programs
If cancer has spread to bones, or if drugs weaken bones, the risk of fractures rises. Physiotherapists can teach balance exercises and safe walking strategies. Home safety checks to remove loose rugs, add grab bars, and improve lighting can prevent falls, preserve independence, and avoid hospital stays.
Sexual health and intimacy counseling
Cancer and its treatments may reduce sexual desire, cause erectile problems, or create body-image worries, especially after surgery scars or weight change. Counseling offers simple communication tools for partners and may suggest safe sexual positions that avoid pressure on the surgical area. Good sexual health supports overall emotional well-being and relationship quality.
Fertility and family-planning counseling
Some systemic drugs and radiation can affect fertility. Before treatment, younger patients may benefit from counseling on sperm banking, egg or embryo freezing, or pregnancy timing. This planning helps people feel less loss of control and offers hope for future family plans, even while dealing with clear cell kidney cancer.
Rehabilitation after nephrectomy
After partial or radical nephrectomy, structured rehab helps you regain movement, strength, and breathing capacity. Simple walking plans, breathing exercises, and gentle stretching reduce complications like blood clots and pneumonia. Rehab also teaches how to protect the surgical side while returning to normal daily tasks and work.
Telemedicine and remote monitoring
Video visits and remote symptom reporting let you stay in close contact with your cancer team without frequent travel to hospital. This is useful for people living far away or feeling very weak. Early reporting of side effects means quicker dose adjustments and supportive care, which can prevent hospital admission.
Education on clinical trials and research participation
Many new treatments for clear cell kidney cancer, especially immunotherapy and targeted drugs, are tested in clinical trials. Education about trial purpose, rights, risks, and benefits helps you decide if a trial is right for you. Trials can offer access to new medicines and also help doctors improve care for future patients.

Drug treatments

Important: The following information is general education, not a prescription. Dose and schedule must always be decided by an oncologist using official FDA prescribing information. Never start or change cancer medicine on your own.

Sunitinib (SUTENT)
Sunitinib is a tyrosine kinase inhibitor (TKI) that blocks signals which tumors use to grow new blood vessels. It is approved for advanced and high-risk renal cell carcinoma. Doctors usually give it as daily capsules in repeating cycles. The main goal is to slow or shrink the tumor. Side effects can include fatigue, high blood pressure, mouth sores, diarrhea, hand-foot skin reaction, and low blood counts, so regular blood tests and blood-pressure checks are needed.
Pembrolizumab (KEYTRUDA) plus Axitinib (INLYTA)
This combination joins an immune checkpoint inhibitor (pembrolizumab) with a VEGF-targeting TKI (axitinib) for first-line treatment of advanced clear cell kidney cancer. Pembrolizumab is given as an intravenous infusion on a schedule, while axitinib is taken as oral tablets. Together, they help the immune system see and attack cancer cells and cut the tumor’s blood supply. Common side effects include fatigue, diarrhea, high blood pressure, liver test changes, and immune-related inflammation of organs such as thyroid or bowel.
Nivolumab (OPDIVO) plus Ipilimumab (YERVOY)
This dual immunotherapy regimen is used for some patients with intermediate- or poor-risk advanced renal cell carcinoma. Both drugs are given by IV infusion over several weeks. They work by blocking different immune checkpoints, allowing T-cells to stay active against cancer. The purpose is long-term disease control and sometimes deep responses. Side effects can include skin rash, diarrhea, hormone gland problems, and inflammation of lungs, liver, or bowel, so close monitoring is vital.
Cabozantinib (CABOMETYX)
Cabozantinib is a TKI that targets several growth-factor receptors involved in tumor growth and bone metastases. It can be used as first-line or later-line therapy for advanced kidney cancer. It is taken once daily as tablets at a dose chosen by the oncologist. Side effects often include diarrhea, nausea, fatigue, hand-foot syndrome, high blood pressure, and sometimes blood clots or bleeding, so regular review is necessary.
Cabozantinib plus Nivolumab
This combination uses cabozantinib to block blood-vessel growth and nivolumab to boost immune responses. It is now a guideline-preferred first-line regimen for many patients with advanced clear cell RCC. The purpose is to improve survival and response rates compared with older single-drug TKIs. Side effects combine those of both drugs, with extra risk of high blood pressure, diarrhea, skin changes, and immune-related organ inflammation.
Lenvatinib (LENVIMA) plus Pembrolizumab
Lenvatinib is another VEGF-targeting TKI that, when combined with pembrolizumab, has shown strong activity in advanced RCC. Lenvatinib is taken orally, while pembrolizumab is given by IV. The mechanism is similar to other ICI+TKI combinations: blocking blood-vessel signals and releasing immune brakes at the same time. Side effects can include high blood pressure, diarrhea, fatigue, and immune-related problems, so blood pressure and lab tests are checked frequently.
Lenvatinib plus Everolimus
For some patients whose cancer has already been treated with other TKIs, lenvatinib can be combined with everolimus, a drug that blocks the mTOR pathway involved in cell growth. Both are taken as oral tablets. This combination aims to control disease after earlier therapies stop working. Common side effects include mouth sores, diarrhea, high blood pressure, increased cholesterol, and low blood counts, so monitoring and dose adjustments are common.
Everolimus (AFINITOR)
Everolimus alone is sometimes used as a later-line option. It is an mTOR inhibitor that slows tumor cell growth and blood-vessel formation. It is taken once daily as a tablet. Side effects can include mouth ulcers, infections, high blood sugar, high cholesterol, fatigue, and lung inflammation, so doctors monitor labs and breathing symptoms closely.
Temsirolimus (TORISEL)
Temsirolimus is an IV mTOR inhibitor used mainly for poor-risk advanced RCC. It works in a similar pathway to everolimus but is delivered by infusion on a weekly schedule. The goal is to slow tumor growth in patients who may not tolerate TKIs or ICIs well. Side effects may include rash, high blood sugar, high cholesterol, low blood counts, and risk of infections.
Belzutifan (WELIREG)
Belzutifan is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. It targets a key pathway that clear cell RCC cells use to grow when oxygen is low. It is approved for advanced RCC after prior immunotherapy and a VEGF-targeted TKI. Belzutifan is taken orally once daily and can offer another option when other regimens fail. Side effects include low red blood cells (anemia), fatigue, low oxygen levels, and dizziness, so oxygen and blood counts are checked.
Pazopanib (VOTRIENT)
Pazopanib is an oral TKI that blocks VEGF receptors and other targets to slow tumor blood-vessel growth. It can be used in advanced RCC, especially in earlier lines before newer IO+TKI combinations became common. The purpose is disease control and symptom relief. Side effects include liver test changes, diarrhea, hair color changes, high blood pressure, and fatigue, so regular lab monitoring is essential.
Sorafenib (NEXAVAR)
Sorafenib is an older TKI that also targets VEGF receptors and other kinases. It is now used less often but can still be an option in certain later-line settings or where newer drugs are not available. It is taken orally twice daily. Side effects include hand-foot skin reaction, diarrhea, rash, high blood pressure, and fatigue.
Tivozanib (FOTIVDA)
Tivozanib is a newer, highly selective VEGF TKI used mainly in previously treated advanced RCC. It aims to provide disease control with possibly a slightly different side-effect profile compared with older TKIs. It is taken orally in repeating cycles. Common side effects include high blood pressure, fatigue, diarrhea, and voice changes.
Avelumab (BAVENCIO) plus Axitinib
This combination uses the PD-L1 inhibitor avelumab with axitinib as first-line treatment in some advanced RCC settings. Avelumab is given IV, and axitinib is taken orally. Together they enhance immune attack and reduce blood-vessel growth. Side effects are similar to other ICI+TKI regimens, including immune-related organ inflammation, diarrhea, and high blood pressure.
Nivolumab monotherapy
After one or more prior treatments, nivolumab alone may be used. It blocks PD-1 on T-cells, helping them recognize and attack cancer cells. It is given by IV every few weeks. Some patients have durable responses for years. Side effects are immune-related and can affect skin, gut, liver, lungs, or hormone glands, so early reporting of new symptoms is very important.
Interleukin-2 (high-dose IL-2)
High-dose IL-2 is an older immune therapy sometimes used in selected, very fit patients with metastatic RCC. It powerfully stimulates T-cells and natural killer cells. In a small number of patients, it can lead to long-lasting complete responses, but it has serious side effects such as low blood pressure, fluid shifts, and organ stress, so it is only given in experienced centers.
Interferon-alpha (with or without Bevacizumab)
Interferon-alpha boosts certain immune responses and was widely used before TKIs and ICIs. It is now rarely used alone but may still appear in some regimens with bevacizumab, a drug that blocks VEGF. Side effects include flu-like symptoms, depression, and fatigue, so doctors now prefer newer drugs when available.
Bevacizumab (AVASTIN) with interferon-alpha
Bevacizumab binds VEGF directly and prevents it from stimulating new blood vessels. In combination with interferon-alpha, it has shown activity in RCC, but it is less common today compared with IO+TKI combos. Side effects include high blood pressure, bleeding, clotting, and wound-healing problems, so timing with surgery is important.
Everolimus plus other TKIs (sequential strategies)
In some treatment plans, everolimus is used after one or more TKIs or ICIs. Sequencing drugs with different mechanisms (VEGF TKIs, mTOR inhibitors, ICIs) aims to keep the cancer under control for as long as possible. The exact order is chosen based on prior response, side effects, and patient health.
Clinical-trial immunotherapies and combinations
New combinations of checkpoint inhibitors, TKIs, HIF-2α inhibitors like belzutifan, and other targeted agents are being studied in trials. These regimens aim to improve survival and reduce toxicity compared with current standards. If standard options are exhausted, your oncologist may discuss a trial as a way to access these emerging treatments.

Dietary molecular supplements

Vitamin D – May support bone health and immune function, which is important if cancer has spread to bones or you receive drugs that thin bones. Dose is usually adjusted based on blood levels. Too much vitamin D can harm kidneys and raise calcium, so never self-dose high amounts.
Omega-3 fatty acids (fish oil) – May help reduce inflammation and support heart health, which is important when TKIs raise blood pressure and affect the heart. Usual doses are modest capsules taken with food. High doses can increase bleeding risk, especially if you are on blood thinners.
Probiotics – These “good bacteria” may help maintain gut health during treatments that cause diarrhea or antibiotic use. Small daily doses in yogurt or capsules can support digestion. Some patients with very low immunity should avoid live probiotics, so always check with your oncology team.
Protein supplements (whey or plant-based) – When appetite is low, shakes or powders can help maintain muscle mass and strength. They provide concentrated protein with limited volume, which is helpful if you feel full quickly. People with reduced kidney function may need lower protein intake, so dietitian advice is essential.
Curcumin (turmeric extract) – Curcumin has anti-inflammatory and antioxidant effects in lab studies, and many patients are interested in it. Typical supplement doses are modest, taken with meals. Evidence in kidney cancer humans is limited, and curcumin may interact with TKIs by affecting liver enzymes, so do not start without medical approval.
Green tea extract (EGCG) – Laboratory data suggest possible anti-cancer and antioxidant effects, but high-dose extracts have been linked to liver injury. If used at all, it should be low dose and carefully discussed with your doctor, especially if your medicines already stress the liver.
Selenium – This trace mineral supports antioxidant enzymes. In some regions with low selenium in soil, small supplement doses may correct deficiency and support general health. Too much selenium can cause hair loss and nerve problems, so dosing must remain within safe ranges.
Coenzyme Q10 (CoQ10) – CoQ10 is involved in energy production in cells and may ease statin-related muscle pain in some people. In cancer patients, it is sometimes used for fatigue, though strong evidence is lacking. It can interact with blood thinners and blood-pressure drugs, so supervision is important.
Resveratrol – A plant compound found in grapes that has antioxidant effects in lab models. Human data in RCC are minimal. Supplements can affect liver enzymes and blood clotting. If considered, it should be at low dose and only with explicit approval from your oncology team.
Medicinal mushroom extracts (such as PSK, reishi) – Some extracts are studied as immune-modulating agents in other cancers. Evidence for clear cell kidney cancer is limited and quality varies by product. They may affect immune function and interact with checkpoint inhibitors, so they should only be used within clinical trials or under expert guidance.

Immune-boosting and regenerative approaches

Checkpoint inhibitors as immune boosters
Drugs like nivolumab and pembrolizumab act as powerful immune boosters by blocking PD-1 or PD-L1, “releasing the brakes” on T-cells. They do not regenerate tissue, but they may allow the immune system to control or shrink tumors for long periods in some patients. These drugs can cause autoimmune-type side effects, which are treated with steroids and other immune-suppressing medicines when needed.
Belzutifan and hypoxia-pathway targeting
Belzutifan targets HIF-2α, a protein activated in low-oxygen tumor conditions, which is common in clear cell RCC. By blocking this pathway, it can slow tumor growth and may change the tumor environment in ways that support other treatments. It is a novel class and represents a more “precise” way to interfere with cancer biology, though it is not a classic immune booster.
Cytokine-based immune stimulation (IL-2)
High-dose interleukin-2, as mentioned earlier, strongly stimulates immune cells. Although older and risky, it is a classic immune-boosting therapy for metastatic RCC, and a small fraction of patients achieve long-term complete responses. Research is looking for safer versions and combinations that keep the benefits with fewer side effects.
Cancer vaccines (experimental)
Personalized cancer vaccines, made from a patient’s own tumor proteins, aim to “teach” the immune system to recognize and attack kidney cancer cells. These are still mostly in early trials. They are given by injection on a schedule and may be combined with checkpoint inhibitors. So far, data are promising but not strong enough to replace standard treatments.
Adoptive T-cell therapies and CAR-T-like approaches
Scientists are exploring ways to remove a patient’s T-cells, engineer or expand them in the lab, and reinfuse them to attack kidney cancer more strongly. This regenerative immune approach has worked in some blood cancers and is being tested in solid tumors like RCC. For now, these treatments are only available in specialized trials.
Growth-factor support for blood cells (G-CSF, EPO, etc.)
While not treating the tumor, growth-factor drugs can help regenerate blood cells when treatments cause low white cells or anemia. Examples include granulocyte colony-stimulating factor and erythropoiesis-stimulating agents in carefully selected patients. Keeping blood counts stable allows people to stay on effective cancer drugs at safer doses. These supportive agents must be used under strict guidelines because they also carry risks.

Surgeries (key procedures)

Partial nephrectomy
In partial nephrectomy, the surgeon removes only the tumor and a small rim of normal kidney tissue. This is often used when the tumor is small and in a favorable location. The purpose is to cure the cancer while saving as much kidney function as possible. It can be done with open, laparoscopic, or robotic techniques.
Radical nephrectomy
Radical nephrectomy removes the entire kidney with the tumor, nearby fat, and sometimes nearby lymph nodes or adrenal gland. It is often used when the tumor is large or in a difficult position. This surgery can cure localized clear cell kidney cancer but leaves you with one kidney, so long-term follow-up of kidney function is important.
Cytoreductive nephrectomy in metastatic disease
When cancer has already spread, removing the main kidney tumor may still help some patients. The idea is to reduce the overall cancer burden and help systemic drugs work better. This approach is not for everyone; it is chosen based on general health, spread pattern, and response to initial systemic therapy.
Metastasectomy (removal of metastatic lesions)
In selected patients with a limited number of metastases, surgeons may remove lung, liver, or bone deposits. This can relieve pain, prevent fractures or bleeding, and sometimes prolong survival. The decision depends on the number and location of metastases and how well systemic drugs are working.
Ablation procedures (cryoablation or radiofrequency ablation)
For small tumors or patients not fit for major surgery, doctors can use needles guided by imaging to freeze (cryoablation) or heat (radiofrequency ablation) the tumor. These minimally invasive procedures aim to destroy cancer cells while sparing the rest of the kidney. They may be repeated if needed and are often done under local or light general anesthesia.

Prevention strategies

Do not smoke, or quit if you do.
Maintain a healthy body weight with active lifestyle and balanced diet.
Keep blood pressure under control with lifestyle and medicines if needed.
Manage diabetes and other metabolic conditions carefully.
Avoid long-term overuse of non-steroidal painkillers unless a doctor advises them.
Limit exposure to harmful chemicals at work and use proper protective equipment.
Drink enough water daily unless you have a medical reason to limit fluids.
Keep alcohol intake low or avoid it.
Eat a diet rich in fruits, vegetables, and fiber rather than processed meat and high-salt foods.
If you have strong family history or conditions like von Hippel–Lindau syndrome, ask about genetic counseling and regular kidney imaging.

When to see doctors

You should see a doctor promptly if you notice blood in your urine, ongoing flank or back pain on one side, a lump in your abdomen, unexplained weight loss, fever that does not go away, or extreme tiredness. People already diagnosed with clear cell adenocarcinoma of the kidney must also see their cancer team urgently for new or worsening shortness of breath, chest pain, sudden swelling, severe diarrhea, yellow eyes or skin, or confusion, because these can be serious drug side effects. Regular scheduled follow-up with imaging and blood tests is essential even when you feel well, to check kidney function and look for recurrence.

What to eat and what to avoid

Eat plenty of colorful fruits and vegetables every day for vitamins, minerals, and fiber.
Choose whole grains like brown rice, oats, and whole-wheat bread instead of refined grains.
Use lean protein sources such as fish, skinless poultry, beans, and lentils; adjust protein if your kidney doctor advises.
Include small amounts of healthy fats from olive oil, nuts, and seeds.
Limit salt by avoiding salty snacks, instant noodles, and heavily processed foods to protect blood pressure and kidney function.
Avoid processed meats like sausages, bacon, and ham, which may increase cancer risk.
Limit sugary drinks and sweets to help control weight and blood sugar.
Keep alcohol intake low or avoid it entirely, especially if your liver is under stress from medicines.
Be cautious with herbal teas and supplements; some can harm the kidney or interact with cancer drugs.
Ask a dietitian for a personal meal plan if you have one kidney or reduced kidney function.

Frequently asked questions (FAQs)

Is clear cell adenocarcinoma of the kidney the same as clear cell renal cell carcinoma?
Yes. Doctors usually say “clear cell renal cell carcinoma (ccRCC).” It is the most common kidney cancer type in adults and is named for the clear look of the cells under the microscope.
Can this cancer be cured?
If the tumor is found early and removed completely with surgery, many patients can be cured. When the cancer has spread, cure is less likely, but modern systemic treatments can control the disease for years in some people.
What stage is the most serious?
Stage IV means the cancer has spread beyond the kidney to distant organs or many lymph nodes. This is the most serious stage, but new combinations of immunotherapy and targeted drugs have improved survival compared with older treatments.
Why do I need systemic treatment after surgery?
Even after the tumor is removed, tiny cancer cells may remain in the body. Adjuvant or later systemic treatment aims to kill these cells or control their growth, reducing the risk of recurrence or managing metastatic disease.
How are treatment plans chosen?
Your team looks at tumor stage, risk group, spread pattern, kidney function, other health problems, and your preferences. They use evidence-based guidelines to decide which surgery, systemic drugs, and supportive care will likely help you most.
Will I lose my kidney?
Some people can have a partial nephrectomy and keep most of the kidney. Others need a radical nephrectomy that removes the whole kidney. The decision depends on tumor size, position, and safety of surgery. Many people live well with one kidney.
Can lifestyle changes really make a difference after diagnosis?
Yes. Quitting smoking, staying active, eating well, and managing blood pressure and weight are linked to better overall health and may improve treatment tolerance and outcomes. They also reduce risk of other serious diseases like heart attack and stroke.
Are all targeted drugs the same?
No. TKIs, mTOR inhibitors, and HIF-2α inhibitors act on different pathways in cancer cells and blood vessels. Some are better suited as first-line therapy, while others are reserved for later lines after prior treatments stop working.
How long will I need systemic treatment?
Many regimens are continued until the cancer progresses or side effects become too strong. Some immunotherapy courses have set durations, after which you may be observed. Your doctor reviews scans and labs regularly to decide whether to continue, adjust, or stop treatment.
What are immune-related side effects?
Checkpoint inhibitors can cause your immune system to attack healthy organs, leading to colitis, hepatitis, thyroiditis, lung inflammation, or other problems. New symptoms like severe diarrhea, cough, or yellow eyes must be reported immediately so steroids or other medicines can be started early.
Can I work during treatment?
Many people continue working, sometimes with reduced hours or lighter duties. Fatigue and clinic visits can make full-time work hard. Discuss adjustments with your employer, and ask your care team for letters or documentation to support work changes if needed.
Is it safe to become pregnant after treatment?
Some drugs can harm a developing baby, so effective contraception is required during treatment and for a time afterward. If you wish to become pregnant later, discuss this early with your oncologist so they can plan timing and fertility preservation if needed.
Do I need special kidney follow-up after nephrectomy?
Yes. Blood tests and sometimes urine tests are done regularly to monitor kidney function. Your doctor may adjust blood-pressure medicines and advise dietary changes to protect the remaining kidney.
Are there foods that “cure” kidney cancer?
No specific food can cure clear cell kidney cancer. However, a healthy diet supports your body during treatment and recovery. Extreme diets or unproven “cancer cures” can be dangerous, especially to your remaining kidney. Always check any special diet with your doctor or dietitian.
Where can I find trustworthy information?
Reliable sources include major cancer centers, national cancer institutes, and guideline organizations that publish patient-friendly kidney cancer booklets. Your care team can recommend websites and printed materials that match your language and reading level.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: January 28, 2025.

PDF Documents For This Disease Condition

References

SaveSavedRemoved 0